Navigation Links
Boehringer Ingelheim Pharmaceuticals, Inc. Statement on RE-ALIGN Data
Date:8/31/2013

or symptoms of blood loss (e.g., a drop in hemoglobin and/or hematocrit or hypotension). Discontinue PRADAXA in patients with active pathological bleeding.
  • Risk factors for bleeding include concomitant use of medications that increase the risk of bleeding (e.g., anti-platelet agents, heparin, fibrinolytic therapy, and chronic use of NSAIDs). PRADAXA's anticoagulant activity and half-life are increased in patients with renal impairment.
  • A specific reversal agent for dabigatran is not available. Hemodialysis can remove dabigatran; however clinical experience for hemodialysis as a treatment for bleeding is limited. Activated prothrombin complex concentrates, recombinant Factor VIIa, or concentrates of factors II, IX or X may be considered but their use has not been evaluated. Protamine sulfate and vitamin K are not expected to affect dabigatran anticoagulant activity. Consider administration of platelet concentrates where thrombocytopenia is present or long-acting antiplatelet drugs have been used.
  • Thromboembolic and Bleeding Events in Patients with Prosthetic Heart Valves
    The safety and efficacy of PRADAXA in patients with bileaflet mechanical prosthetic heart valves (recently implanted or implanted more than 3 months prior to enrollment) was evaluated in the phase 2 RE-ALIGN trial. RE-ALIGN was terminated early because of significantly more thromboembolic events (valve thrombosis, stroke, transient ischemic attack, and myocardial infarction) and an excess of major bleeding (predominantly post-operative pericardial effusions requiring intervention for hemodynamic compromise) for PRADAXA vs warfarin. Therefore, the use of PRADAXA is contraindicated in patients with mechanical prosthetic valves.

    Use of PRADAXA for the prophylaxis of thromboembolic events in patients with AFib in the setting of other forms of valvular heart disease, including bioprosthetic heart valve, has not been studied and is not recommended.

    Ef
    '/>"/>

    SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. Boehringer Ingelheim Announces Launch of GLORIA™-AF Registry in Newly-Diagnosed Patients with Non-Valvular Atrial Fibrillation
    2. New Data to be Presented at the Annual American Thoracic Society International Conference Demonstrates Depth of Boehringer Ingelheim Respiratory Research Pipeline
    3. Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012
    4. Results of Phase II Study of Boehringer Ingelheims Investigational Bronchodilator for COPD Presented at 2012 ATS International Conference
    5. Boehringer Ingelheim Presents First Data for Tiotropium in Adolescents with Moderate Persistent Asthma
    6. Lilly and Boehringer Ingelheim Present Data at the 72nd American Diabetes Association Scientific Sessions® from Phase II Studies Comparing Investigational Novel Basal Insulin to Insulin Glargine
    7. Boehringer Ingelheim and Lilly introduce the My Well Planner Lifestyle Improvement Program for Adults with Type 2 Diabetes
    8. Boehringer Ingelheim announces afatinib expanded access program (EAP) for patients with EGFR mutation-positive advanced NSCLC
    9. Whistleblowers extraordinary efforts helped win $95 million settlement with Boehringer Ingelheim
    10. Phase 2b Data of Boehringer Ingelheims Interferon-Free Hepatitis C Treatment Show Viral Cure Achieved in Up to 85% of Treatment-Naive Patients
    11. Boehringer Ingelheim Announces Equine Research Awards
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/27/2014)... Aug. 28, 2014 China Nepstar Chain ... the "Company"), a leading retail drugstore chain in ... stores, today announced its unaudited financial results for ... Financial HighlightsFor the quarter ended June 30, 2014: ... million) compared to RMB638.8 million in the second ...
    (Date:8/27/2014)... , Aug. 27, 2014 TWi Pharmaceuticals, ... approval from the United States Food and Drug ... (ANDA) for megestrol acetate 125mg/ml oral suspension, the ... is the first-to-file and under Hatch Waxman rules, ... marketing exclusivity.  TWi has completed the pre-launch preparation ...
    (Date:8/27/2014)... 27, 2014 Reportbuyer.com has added ... Collaborative R&D Terms & Agreements in Pharma, ... The Collaborative R&D Terms and ... provides comprehensive understanding and unprecedented access to ... into by the worlds leading life science ...
    Breaking Medicine Technology:China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 2China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 3China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 4China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 5China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 6China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 7China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 8China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 9China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 10China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 11TWi Pharmaceuticals Receives US FDA Final Approval on Generic Megestrol Acetate 125mg/ml Oral Suspension 2Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics 2Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics 3Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics 4Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics 5Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics 6Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics 7Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics 8Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics 9
    ... Mylan Inc. (Nasdaq: MYL ) today ... final approval from the U.S. Food and Drug Administration ... Ibandronate Sodium Tablets, 150mg. This product is the generic ... treatment and prevention of osteoporosis in postmenopausal women. ...
    ... YORK, March 20, 2012 Reportlinker.com ... report is available in its catalogue: ... Market: Western Europe Market Size, Segment ... http://www.reportlinker.com/p0797078/Nutraceuticals-Product-Market-Western-Europe-Market-Size-Segment-And-Country-Analysis-And-Forecasts-2007-2017.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Nutraceutical ...
    Cached Medicine Technology:Nutraceuticals Product Market: Western Europe Market Size, Segment And Country Analysis And Forecasts (2007-2017) 2Nutraceuticals Product Market: Western Europe Market Size, Segment And Country Analysis And Forecasts (2007-2017) 3Nutraceuticals Product Market: Western Europe Market Size, Segment And Country Analysis And Forecasts (2007-2017) 4
    (Date:8/28/2014)... 2014 Alpine, NJ resident Othon Mourkakos ... team, Zebras In Tiaras, to benefit the Immune Deficiency ... October 26, 2014 in Foley Square, New York. ... Primary immunodeficiency diseases (PI) are a group of more ... of the body’s immune system is missing or functions ...
    (Date:8/28/2014)... CA (PRWEB) August 28, 2014 MarijuanaDoctors.com ... California physician, James Patel M.D. of Livermore, California. As ... best and most qualified physicians, and in accordance with ... our patients to Dr. Patel’s practice. , Initially finding ... a young age, Dr. Patel was shaped by his ...
    (Date:8/28/2014)... (PRWEB) August 28, 2014 MMAR Medical ... program is a chance for regular customers to enjoy ... without the need for a wholesale license. It’s a ... semi-professional athletic programs and others who regularly purchase medical ... , “Whether supporting your own active lifestyle or those ...
    (Date:8/28/2014)... 28, 2014 The Pulmonica is a ... resonant, meditative sounds that can be felt vibrating in ... to use it – just taking long, slow, deep ... , Here are some examples of how to ... your eyes, relax, and maintain good posture. Try to ...
    (Date:8/28/2014)... 28, 2014 Coveros, Inc., the ... that it has partnered with InfoZen on the ... start date of 2/4/2014 with U.S. Citizenship and ... (DHS) agency that oversees lawful immigration to the ... InfoZen will automate the integration and delivery of ...
    Breaking Medicine News(10 mins):Health News:Army Colonel Dr. James Patel Joins the Medical Marijuana Industry 2Health News:Army Colonel Dr. James Patel Joins the Medical Marijuana Industry 3Health News:Army Colonel Dr. James Patel Joins the Medical Marijuana Industry 4Health News:MMAR Medical Announces Customer Membership Program 2Health News:Ever Thought of Meditating With a Harmonica; Harmonica Techs, Inventors of the Pulmonica® Pulmonary Harmonica®, Present Tips on How to Relax with Soothing Sounds 2Health News:Coveros Partners with InfoZen on USCIS Transformation Integration Award 2
    ... 1, 2011) Two new studies published in the ... (JNM) provide insight into the potential of positron ... and to identify pharmaceuticals to slow the progress of ... the Alzheimer,s Association guidelines for detecting Alzheimer,s-related brain changes ...
    ... , MONDAY, Aug. 1 (HealthDay News) -- Despite the ... -- which can be done at home or in day ... However, colon cleansing can cause serious side effects ranging ... the report say. Colon cleansing -- also called colonic ...
    ... breast cancer patients who don,t respond to tamoxifen ... from the Kimmel Cancer Center at Jefferson ... combined with dasatinib, a protein-tyrosine kinase inhibitor, reverses ... surrounding tissue by normalizing glucose intake and reducing ...
    ... , SUNDAY, July 31 (HealthDay News) -- A ... been pinpointed by a team of researchers working together ... The PYHIN1 gene variant was not present in ... gene variant to be identified in black Americans. ...
    ... obesity are heavily rooted in the notion of personal ... healthy foods and portion sizes consistent with weight loss ... According to preventive medicine and behavioral experts at Rush ... that views obesity as a result of neurobehavioral processes ...
    ... By Amanda Gardner HealthDay Reporter , FRIDAY, ... Drug Administration should scrap the system it uses to ... joints and heart pacemakers, according to a highly anticipated ... come up with a legally sound process that ensures ...
    Cached Medicine News:Health News:New JNM research supports upcoming Alzheimer's disease guidelines 2Health News:Colon Cleansing Has No Health Benefit, May Harm: Report 2Health News:Leukemia drug reverses tamoxifen-resistance in breast cancer cells 2Health News:Obesity counseling should focus on neurobehavioral processes, not personal choice, researchers say 2Health News:Obesity counseling should focus on neurobehavioral processes, not personal choice, researchers say 3Health News:Report Urges New Review System for Medical Devices 2Health News:Report Urges New Review System for Medical Devices 3
    Full Handle Laseredge Implant Blade Knife, 5.2 mm angled bevel up. Blade dimension: 16.5 mm x 5.2 mm x 4.2 mm x 1.6 mm....
    Full Handle Laseredge Crescent Blade Knife, angled double bevel. Blade tip dimension: 12.7 mm x 2.0 mm x 3.8 mm....
    Full Handle Laseredge Stab Blade Knife, 22.5 blade. Blade tip dimension: 10.7 mm x 1.8 mm x 4.2 mm....
    18 gauge straight. Fine tip. Lightweight design offers precise hemostasis. Pencil design minimizes tissue trauma and induced astigmatism. Knurled handle provides a sure grip and better manipulation....
    Medicine Products: